Autologous human adipose tissue derived bone tissue therapy - Bonus BioGroup

Drug Profile

Autologous human adipose tissue derived bone tissue therapy - Bonus BioGroup

Alternative Names: Bone graft for maxillofacial applications - Bonus BioGroup; BonoFill; BonoFill-II; HATDCs - Bonus BioGroup; Human Adipose Tissue Derived Cells - Bonus BioGroup

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bonus BioGroup
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bone disorders

Most Recent Events

  • 23 Mar 2017 Phase-I/II development for Bone disorders (maxillofacial) is ongoing in Israel (Implant)
  • 24 Jan 2017 BonusBio Group plans a phase I/II trial for Bone disorders in Israel (NCT03024008)
  • 01 Jan 2017 BonusBio Group initiates enrolment in phase I/II for Bone disorders in Israel (NCT03024008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top